Introduction Pancreatoduodenectomy (PD) is one of the most complex abdominal operations to perform, and it is usually conducted for tumours of the periampullary region and chronic pancreatitis. Minimally invasive surgery has been progressively being developed for pancreatic surgery, first with the advent of hybrid-laparoscopy and recently with total laparoscopic surgery. Issues including the safety and efficacy of total laparoscopic pancreaticoduodenectomy (TLPD) and open pancreaticoduodenectomy (OPD) are currently being debated. Studies comparing these two surgical techniques are emerging, and large randomized controlled trials (RCTs) are lacking but are clearly required. Methods and analysis TJDBPS01 is a multicentre, prospective, randomized controlled, parallel-group, superiority trial in fourteen centres with pancreatic surgery experts who have performed ≥104 TLPDs and OPDs. A total of 656 patients who will undergo PD are randomly allocated to the TLPD group or OPD group in a 1:1 ratio. The trial hypothesis is that TLPD has superior or equivalent safety and advantages in postoperative recovery compared with OPD. The primary outcome is the postoperative length of stay (LOS). Ethics and dissemination The Instituitional Review Board Approval of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology has approved this trial and will be routinely monitoring the trial at frequent intervals, as will an independent third-party organization. Any results from this trial (publications, conference presentations) will be published in peer-reviewed journals and conference proceedings.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
656
Total laparoscopic pancreaticoduodenectomy
Open pancreaticoduodenectomy
Tongji Hospital
Wuhan, Hubei, China
RECRUITINGLength of stay
Length of stay was defined as the postoperative time interval in days
Time frame: Up to 24 months
Estimated blood loss
The amount of blood loss during surgical procedure.
Time frame: Up to 24 months
Operation time
Time between first incision and last skin closure.
Time frame: Up to 24 months
Mortality
Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.
Time frame: Up to 24 months
Complication rate
Clavien-Dindo
Time frame: Up to 24 months
CCI
comprehensive complication index
Time frame: Up to 24 months
2 year survival
Overall survival rate for 24 months after surgery
Time frame: Up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.